We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-10.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.32B
AUM Growth
+$99.8M
Cap. Flow
+$327M
Cap. Flow %
24.74%
Top 10 Hldgs %
52.92%
Holding
77
New
22
Increased
20
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$86.8M
2
RAD
Rite Aid Corporation
RAD
+$67.2M
3
PEN icon
Penumbra
PEN
+$63.2M
4
SAGE
Sage Therapeutics
SAGE
+$52.5M
5
INCY icon
Incyte
INCY
+$50.3M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$85.4M
2
AGN
Allergan plc
AGN
+$41.5M
3
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$36.3M
4
HCA icon
HCA Healthcare
HCA
+$35.4M
5
ABBV icon
AbbVie
ABBV
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 9.13%
3 Communication Services 1.09%
4 Industrials 1%
5 Technology 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$117M 8.83%
8,332,930
+2,035,407
+32% +$31.9M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$88.1M 6.67%
957,634
+198,155
+26% +$17.1M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$80.9M 6.13%
17,750,510
+4,126,890
+30% +$24.5M
MDVN
4
DELISTED
MEDIVATION, INC.
MDVN
$74.5M 5.64%
+1,752,642
New +$86.8M
INCY icon
5
Incyte
INCY
$25.2B
$67.7M 5.13%
613,598
+448,603
+272% +$50.3M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$42.5B
$64.2M 4.87%
1,137,559
+170,200
+18% +$11M
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$53.6M 4.06%
1,390,173
+860,974
+163% +$38.8M
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$53M 4.01%
1,322,592
+712,421
+117% +$23.2M
PEN icon
9
Penumbra
PEN
$12.7B
$51M 3.86%
+1,562,587
New +$63.2M
RAD
10
DELISTED
Rite Aid Corporation
RAD
$49M 3.71%
+403,570
New +$67.2M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$48.4M 3.66%
1,142,864
+852,514
+294% +$52.5M
WCG
12
DELISTED
Wellcare Health Plans, Inc.
WCG
$44.3M 3.36%
+514,273
New +$45.1M
CMRX
13
DELISTED
Chimerix, Inc.
CMRX
$40.8M 3.09%
1,067,978
+368,553
+53% +$18.2M
CNC icon
14
Centene
CNC
$32B
$40.5M 3.07%
+1,494,920
New +$50M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$12.5B
$38.8M 2.94%
368,775
+161,031
+78% +$21.5M
ZSPH
16
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$33.8M 2.56%
514,107
+211,119
+70% +$12.7M
ATRA icon
17
Atara Biotherapeutics
ATRA
$92.3M
$33M 2.5%
41,991
+27,085
+182% +$33M
PTLA
18
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$32.8M 2.49%
769,641
+616,941
+404% +$29.8M
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$30.2M 2.29%
+1,462,699
New +$30M
NSTG
20
DELISTED
NanoString Technologies, Inc.
NSTG
$22.2M 1.68%
1,385,641
-74,101
-5% -$1.16M
CLDX icon
21
Celldex Therapeutics
CLDX
$3.07B
$20.6M 1.56%
130,268
+128,084
+5,865% +$36.3M
DBVT
22
DBV Technologies
DBVT
$851M
$19M 1.44%
+53,282
New +$21M
DVAX
23
DELISTED
Dynavax Technologies
DVAX
$17.8M 1.35%
+724,348
New +$20.5M
INSM icon
24
Insmed
INSM
$25.9B
$17.6M 1.33%
947,966
+80,620
+9% +$2.01M
MODN
25
DELISTED
MODEL N, INC.
MODN
$14.4M 1.09%
1,443,278
– –
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2015 Portfolio in Review

As of Q3 2015, Redmile Group held 77 positions worth $1.32B, up 8.2% from $1.22B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group deployed $327M of net new capital in Q3 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $25.7M trimmed.

  • Redmile Group's largest Q3 2015 buy was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
  • Redmile Group added most to Sage Therapeutics in Q3 2015, an estimated $52.5M increase.
  • Redmile Group's biggest Q3 2015 reduction was Jazz Pharmaceuticals, cutting an estimated $25.7M.
  • Redmile Group fully exited Bausch Health in Q3 2015, selling an estimated $85.4M.
  • Redmile Group's ten largest holdings make up 53% of its $1.32B portfolio in Q3 2015.
  • Redmile Group opened 22 new positions and closed 19 in Q3 2015.
  • Redmile Group's portfolio value rose 8.2% quarter-over-quarter to $1.32B.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.